Vaccination & Immunization Information in Los Angeles

In November 2023, the U.S. Food and Drug Administration granted approval for a chikungunya virus vaccine designated for individuals aged 18 years and above. Currently, an Advisory Committee on Immunization Practices (ACIP) Work Group is meticulously examining the data related to this chikungunya vaccine. The focus is on assessing its suitability for use among individuals in the United States who are vulnerable to chikungunya, such as those who engage in international travel, laboratory personnel handling the chikungunya virus, and residents of U.S. states and territories with existing or potential transmission risks. The Work Group is actively formulating vaccine recommendations for consideration by ACIP. Once finalized, these recommendations will be published on the CDC’s ACIP vaccine website. Please stay tuned for updates and refer back to the website for the most recent information.